Form 4: Odyssey Therapeutics CEO Reports Equity Conversion and Grant

CEO Gary D. Glick reports the conversion of preferred stock into common shares and the receipt of a new stock option grant.

Summary

• Reporting person Gary D. Glick, President and CEO of Odyssey Therapeutics, Inc., executed a conversion of Series C and Series D Preferred Stock into Common Stock.
• The conversion occurred on May 11, 2026, in connection with the company's initial public offering.
• A total of 27,386 shares of Common Stock were acquired through these conversions.
• The CEO was granted a new stock option for 884,450 shares of Common Stock with an exercise price of $18.00 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing related to post-IPO equity adjustments and standard executive compensation, carrying neutral sentiment.

Positives

• Alignment of executive interests through significant equity ownership and new option grants.
• Successful conversion of preferred stock into common equity, simplifying the capital structure post-IPO.

Negatives

• Dilutive impact of new stock option grants to the CEO.

Risks

• Vesting of stock options is contingent upon continued service, creating potential retention risk if the executive departs.
• Market volatility risks associated with the newly public status of the company.

Future Outlook

The CEO's stock options are set to vest in 48 equal monthly installments starting June 7, 2026, incentivizing long-term service.

Management Comments

• The reporting person serves as the President and Chief Executive Officer of the issuer.

Industry Context

StockSavvy.ai notes that post-IPO equity restructuring and executive compensation grants are standard practices for biotech firms transitioning to public markets to ensure leadership alignment with shareholder value.

Comparison to Industry Standards

• The 48-month vesting schedule for executive options is consistent with standard industry practices for early-stage public biotechnology companies.
• Conversion of preferred stock to common stock at the time of an IPO is a standard mechanism to clean up the capital structure.

Stakeholder Impact

• Shareholders may experience minor dilution from the new option grants.
• The conversion of preferred stock simplifies the equity structure, which is generally positive for transparency.

Next Steps

• Commencement of option vesting on June 7, 2026.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Equity Conversion, Biotech